Repros Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Repros Therapeutics sits in the top decile of US sponsors by registered trial count (#377 of 15,742 sponsors by registered trial count).
Repros Therapeutics: 50 sponsored US clinical trials, none currently recruiting.
Repros Therapeutics sponsors 50 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 38 completed. 13 of these trials are in Phase 3-4 (later-stage) and 37 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Secondary Hypogonadism, with 2 trials.
Top-decile sponsor footprint
Repros Therapeutics ranks in the top decile of sponsors by registered trial count (#377 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
38 of 50 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
50 total, page 1 of 1
An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
NCT02811159
A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene
NCT02651688
A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
NCT02301897
Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids
NCT02323646
An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration
NCT02274181
An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal
NCT02169804
Comparison of Two Formulations of Proellex for Oral Administration
NCT02141061
Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males
NCT01991327
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
NCT01993225
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
NCT01993212
Comparison of Two Formulations of Androxal
NCT01984398
A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal
NCT01959685
Comparison of Two Formulations of Proellex for Vaginal Administration
NCT01962805
Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function
NCT01923857
Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function
NCT01923870
Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis
NCT01728454
Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism
NCT01739595
Extension of Study ZPV-200
NCT01631903
Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism
NCT01619683
Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism
NCT01532414
Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
NCT01534208
Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids
NCT01451424
A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203
NCT01386567
The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)
NCT01386606
Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism
NCT01270841
Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus
NCT01191320
Determination of the Lowest, Safe and Effective Dose of Proellex
NCT01187043
Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females
NCT00881062
Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids
NCT01069120
Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study
NCT00958412
Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids
NCT00853567
Study to Evaluate Menses Induction in Women Administered Proellex
NCT00881608
Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults
NCT00741273
Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females
NCT00787618
Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids
NCT00737282
Crossover Study of the Safety and PK Properties of Proellex®
NCT00749879
Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids
NCT00735553
Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects
NCT00741468
To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone
NCT00706719
Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids
NCT00702702
An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext
NCT00958893
Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
NCT00683917
Proellex® Pharmacokinetic Bridging Study II
NCT00620503
A Safety and Pharmacokinetic Study of Proellex®
NCT00619385
Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis
NCT00556075
Proellex Pharmacokinetics Bridging Study
NCT01067807
Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003
NCT00958334
Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism
NCT00962637
Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism
NCT01067365
Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
NCT00882258
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 18 |
| Phase 3 | 13 |
Therapeutic Areas
How the Repros Therapeutics early-phase archive is shaped
50 indexed studies, none listed as recruiting (0% open); 38 completed (76%).
Phase mix: 13 late (III/IV) vs 37 early (I/II) (early-phase heavy).
Top condition: Secondary Hypogonadism (2 trials), 8 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Repros Therapeutics: archived-pipeline peers nationwide
Peers matched on 50 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Repros Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 50 archived trials
- Carelon Research · 50 trials · 2% recruiting
- The University of Texas at Dallas · 50 trials · 28% recruiting
- Colgate Palmolive · 51 trials · 6% recruiting
- MedtronicNeuro · 51 trials · 4% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Repros Therapeutics page
50 registered trials is a research-attention snapshot, not an endorsement of Repros Therapeutics or any single study.
- None of Repros Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Secondary Hypogonadism is the condition Repros Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Secondary Hypogonadism trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Repros Therapeutics pipeline card: 50 registered trials from official public datasets.Report a data error.